Arrogene, Inc., a development stage company, engages in developing nano-biopolymers and related technologies cancer therapeutics and diagnostics in the United States. Its products include nanopolymer Polycefin that is in pre-clinical development to block Laminin-411 production in primary and metastatic brain and breast tumors; Laminin-411, a diagnostic tool for advanced brain glioma and as a prognostic indicator that predicts disease recurrence; and Laminin-421. The company was founded in 2007 and is based in Santa Monica, California.
Funding Rounds (6) - $4.67MUpdate
Current Team (4)Update
Santa Monica, CA 90404